or Try an Advanced Search...

    Treatment Of Hemophilia Stocks List

    Symbol Grade Name % Change
    ALNY B Alnylam Pharmaceuticals, Inc. 0.13
    BIIB C Biogen Idec Inc. -0.02
    CNTA D Centessa Pharmaceuticals plc -2.55
    QURE F uniQure N.V. -0.78
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics

    Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Hemophilia stocks.

    Symbol Grade Name Weight
    FBT B First Trust Amex Biotech Index Fund 8.89
    BIS F ProShares UltraShort Nasdaq Biotechnology 8.07
    BBH B Market Vectors Biotech ETF 7.76
    IBBQ A Invesco Nasdaq Biotechnology ETF 6.76
    IBB B iShares Nasdaq Biotechnology Index Fund 6.49
    View all Treatment Of Hemophilia ETFs...
    Compare ETFs
    Compare BIS to IBB Compare BIS to IBBQ Compare FBT to BBH

        Treatment Of Hemophilia Stocks Recent News

        Date Stock Title
        Jul 1 QURE uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
        Jul 1 QURE Genezen to buy uniQure's gene therapy operations in Lexington
        Jul 1 QURE Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
        Jul 1 QURE uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
        Jul 1 QURE UniQure, with sale of plant, outsources Hemgenix manufacturing
        Jul 1 BIIB 10 clinical trials to watch in the second half of 2024
        Jul 1 ALNY Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2
        Jun 30 ALNY Rivian Automotive And Carvana Were Among The 10 Biggest Large Cap Gainers Last Week (June 23-June 29): Are These In Your Portfolio?
        Jun 29 ALNY Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders
        Jun 28 BIIB Biogen, Eisai launch Alzheimer's drug Leqembi in China
        Jun 28 BIIB Eisai and Biogen launch LEQEMBI for Alzheimer’s in China
        Jun 28 BIIB Eisai and Biogen launch Alzheimer's drug Leqembi in China
        Jun 27 BIIB “LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
        Jun 27 ALNY Peering Into Alnylam Pharmaceuticals's Recent Short Interest
        Jun 27 ALNY Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
        Jun 26 BIIB FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
        Jun 26 BIIB Pharma M&A: The top high value deals in 2023
        Jun 25 ALNY Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
        Jun 25 BIIB Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?
        Jun 25 ALNY Top Three US Stocks Estimated Below Intrinsic Value In June 2024
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Hemophilia Acute Intermittent Porphyria Biopharmaceutical Biotechnology Clinical Development Deficiency Hemophilia A Idiopathic Pulmonary Fibrosis Lupus Spinal Muscular Atrophy Adeno Associated Virus Alipogene Tiparvovec Alnylam Pharmaceuticals Alpha 1 Antitrypsin Alpha 1 Antitrypsin Deficiency Alzheimer's Disease Amyloid Amyloidosis Antitrypsin Deficiency Applied Genetics
        Treatment Of Hemophilia

        Treatment of hemophilia typically involves the use of replacement therapy, which involves infusions of clotting factor concentrates. These concentrates are made from donated human plasma and are designed to replace the missing clotting factor in the blood. Other treatments may include physical therapy, medications to reduce pain and swelling, and surgery to repair damaged joints.

        Browse All Tags